Novo touts early data for next-gen oral weight loss drug as it outlines next steps

No­vo Nordisk’s oral amy­cretin showed a 13.1% weight loss in pa­tients af­ter just 12 weeks in a small Phase I tri­al, the com­pa­ny re­vealed at its cap­i­tal mar­kets day in Copen­hagen on Thurs­day.

The drug, a co-ag­o­nist to both GLP-1 and amylin re­cep­tor, is al­so be­ing test­ed in its sub­cu­ta­neous form. That Phase I tri­al is set to read out next year, at which point clin­i­cal de­vel­op­ment plans will be de­fined.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.